Back to results
US 2022/0016230 A1Published application
Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5np3
AssigneeValneva SE
InventorsAndrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
Life of this patent
Estimating the term…
Abstract
The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
Claims18
A pharmaceutical composition comprising:
- (i) CHIKV-Δ5nsP3 particles expressing an E2 structural protein as defined by the amino acid sequence of SEQ ID NO:
- 2;
- (ii) CHIKV-Δ5nsP3 particles expressing an E2 structural protein having a mutation E168K in the amino acid sequence of SEQ ID NO:
- 2;
- and
- (iii) optionally a pharmaceutically acceptable excipient,
- wherein 1-50% of the CHIKV-Δ5nsP3 particles present in the composition express the E2 structural protein having the E168K mutation.
4 more elements
A process for producing a pharmaceutical composition comprising CHIKV-Δ5nsP3 particles which express an E2 structural protein as defined by the amino acid sequence of SEQ ID NO:
- 2 comprising the step of:
- growing CHIKV-Δ5nsP3 particles on host cells in such a way as to minimize the presence of immunogenicity-reducing mutations of the virus.
Dependencies are inferred from the claim text.